Recent Updates
Recently added Catalysts

GH Research PLC

GHRS
Richly ValuedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$21.11
▲ +0.66 · +3.23%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GHRS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $12.0452W HIGH $31.44
Volume
146.04 K
Value Traded
6.35 M
Short % Float
5.31%
-4.78%Week
-22.62%1 Month
-16.73%3 Month
+29.19%6 Month
+0.55%5 Year
+0.55%All Time

Cash Data

Unlock GHRS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.45 B
EPS (TTM)
-0.91
P/E Ratio
-
Ent. Value
1.25 B
Total Shares
68.61 M
Float Shares
50.91 M
Insiders
25.83%
Institutions
69.82%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every GHRS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GHRS Catalyst Timeline

Dated clinical, regulatory and corporate events for GH Research PLC

Catalyst Timeline

Dated clinical, regulatory & corporate events for GH Research PLC

145Total events
1Upcoming
40Tier-1 (high impact)
2021 to 2026Coverage

Upcoming catalysts 1

T2Trial Initiation
Subscribe to view catalyst details
GH001

Event history 50

◆Oral PresentationGH001Presentation
Oral presentation of Phase 2b TRD safety results at CINP 2026
treatment-resistant depressionsource ↗
◆Oral PresentationGH001Presentation
Oral presentation of Phase 2b TRD efficacy results at CINP 2026
treatment-resistant depressionsource ↗
▲Full ResultsGH001Clinical Data
Publication of Phase 2a PPD full results in The Journal of Clinical Psychiatry
postpartum depressionsource ↗
▲Oral PresentationGH001Presentation
Post-hoc analysis of MADRS anhedonia factor presented at ASCP Annual Meeting
treatment-resistant depressionsource ↗
◆Poster PresentationGH001Presentation
Three posters accepted at ASCP Annual Meeting 2026
treatment-resistant depression (TRD) and bipolar II depressionsource ↗
▲Enrollment CompleteGH001Trial
GH001-HV-106 study enrolment completed
healthy volunteerssource ↗
▲Dose Finding UpdateGH001Trial
Doses selected for global Phase 3 pivotal program based on GH001-HV-106 results
treatment-resistant depression (TRD)source ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results reported
source ↗
▼Equity OfferingCorporate
Pricing of $117.5 million underwritten offering of ordinary shares at $18.00 per share
source ↗
▼Equity OfferingCorporate
Underwritten offering completed in April 2026, net proceeds $111.2 million
source ↗
Unlock the full GHRS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GHRS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-05-26GH001 Phase 2b data readout Phase 2b
Unlock 3 more GHRS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D24 / 100
Pipeline Score
$7M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 85%
Micro Cap
(rank 561 of 660)
Percentile Rank
GH Research PLC faces pipeline headwinds (24/100), with $106M risk-adjusted pipeline value, led by GH001 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
GH001 Small moleculeCompletedNCT04698603Treatment Resistant DepressionPhase 2 COMPLETED 97Nov 6, 2021
Unlock the GHRS pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every GHRS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
GH001 postpartum depressionPhase 2a2026-06-04all 10 participants experienced rapid remission within hours of treatment, with effects lasting until Day 8 and a favorable safety profileRead MoreGH Research Announces Publication of Phase 2a Postpartum Depression Results Dublin, IrelandRead More
Scroll for more · summaries link to the source press release
Unlock every GHRS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GHRS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full GHRS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in GHRS

Fund % of Portfolio Current MV Shares Owned Activity
BVF INC/IL 5.9 % (51.3 %) 232.52 M 8.65 M
Unlock every fund holding GHRS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GHRS
Shares held by hedge funds each quarter, and who bought or sold.

GHRS Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock GHRS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GHRS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GHRS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GHRS ranks across every disease it competes in

Competitive Position is a premium feature
See how GHRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GHRS News

GHRS
Aug 6, 2026
GHRSFDA Updates
▲ +5.2%on this news

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GH Research PLC reported its financial results for Q2 2026, highlighting successful Phase 1 trials for GH001 and FDA alignment for Phase 3 plans. The company has strengthened its patent estate for mebufotenin and published positive results for postpartum depression. However, the net loss increased, raising concerns about rising R&D expenses.

Read more →
GHRS
Jun 4, 2026
GHRSPhases

GH Research Announces Publication of Phase 2a Postpartum Depression Results Dublin, Ireland

GH Research PLC announced the publication of results from its Phase 2a trial of inhaled mebufotenin for postpartum depression (PPD). The study showed that all 10 participants experienced rapid remission within hours of treatment, with effects lasting until Day 8 and a favorable safety profile. Additionally, the company has two oral presentations accepted for the upcoming World Congress of Neuropsychopharmacology, about ongoing trials related to treatment-resistant depression. These developments represent significant progress in the search for effective therapies for patients with PPD.

Read more →
GHRS
May 21, 2026
GHRSPhases

Apparent sadness Reported sadness Concentration difficulty Lassitude Inability to feel Mean (SD) Change from Baseline in MADRS Anhedonia Factor Items at Day 8 Results Disposition and Baseline Characteristics Disposition

GH Research's clinical trial evaluated GH001, a mebufotenin formulation, for efficacy in patients with treatment-resistant depression (TRD). The Phase 2b study showed significant improvements in the Montgomery- sberg Depression Rating Scale (MADRS) anhedonia factor scores, with rapid reductions observed at Day 8. Results indicated that GH001 not only enhanced the ability to experience pleasure but also had sustained effects through a subsequent open-label extension phase. Overall, the findings support GH001's potential to improve quality of life in TRD patients.

Read more →
GHRS
May 14, 2026
GHRSGeneral

GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended

GH Research PLC reported its unaudited condensed consolidated interim financial results for the three months ended March 31, 2026. The company experienced a significant increase in losses, with a loss before tax of $18,967k, compared to $10,812k in the same period last year. Operating expenses surged, particularly in research and development, contributing to a comprehensive loss of $18,229k. The group's total assets decreased from $288,230k to $275,267k during the same timeframe, highlighting potential financial challenges.

Read more →
GHRS
May 14, 2026
GHRSFDA Updates

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research PLC reported its financial results for Q1 2026, highlighting significant progress in its clinical trials for GH001, a treatment for treatment-resistant depression (TRD). The company completed enrolment for several studies, including a Phase 3 pivotal program and a Phase 1 trial in the U.S. Financially, GHRS holds $267.3 million in cash but reported a net loss of $19 million for the quarter. Positive results from the Phase 2b trial were published, indicating potential efficacy for their lead product candidate.

Read more →
GHRS
May 13, 2026
GHRSGeneral

Notice of Annual General Meeting to be held on 25 June 2026 GH Research plc (the Company or GH Research ) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be t

GH Research plc has announced its Annual General Meeting (AGM) to take place on June 25, 2026, in Dublin, Ireland. The meeting will focus on the re-election of board directors and the appointment of independent auditors. Shareholders will have the opportunity to review the audited financial statements from 2025. The board recommends that shareholders vote in favor of the proposed resolutions, emphasizing the commitment of the directors to the company's interests.

Read more →
GHRS
Apr 29, 2026
GHRSGeneral

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research PLC has announced the pricing of an underwritten offering of 6,527,779 ordinary shares at $18.00 per share, aiming to raise approximately $117.5 million. The offering is set to close on April 30, 2026, and is managed by several financial institutions. The proceeds will support the company's efforts in developing treatments for depression.

Read more →
GHRS
Apr 20, 2026
GHRSFDA Updates
▲ +17.2%on this news

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research PLC has expressed support for a recent White House Executive Order aimed at accelerating medical treatments for serious mental illnesses, including psychedelic therapies. The company is advancing its product candidate, GH001, towards a global pivotal Phase 3 program for treatment-resistant depression. The Executive Order aligns with GH Research's commitment to innovative, evidence-based therapies.

Read more →
GHRS
Mar 25, 2026
GHRSPhases

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GH Research PLC announced the publication of Phase 2b results for GH001 in treatment-resistant depression (TRD) in JAMA Psychiatry. The study demonstrated that GH001's efficacy remains consistent regardless of the number of prior antidepressant treatment failures. This finding supports the potential of GH001 as a transformative therapy for patients with TRD.

Read more →
GHRS
Mar 5, 2026
GHRSPhases
▼ -5.1%on this news

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

GH Research PLC reported its financial results for 2025, highlighting the completion of its Phase 2b trial for GH001 in treatment-resistant depression (TRD). The trial met its primary endpoint, showing significant efficacy. The company is now seeking FDA alignment for its Phase 3 program, with a strong cash position of $280.7 million to support its initiatives. However, it reported an increased net loss compared to the previous year.

Read more →
GHRS
Jan 15, 2026
GHRSPhases

Exploring the Therapeutic Potential of Mebufotenin (GH001) Across Depressive Disorders ACNP 2026 Mini Panel Chair Michael E. Thase, MD Presenters Lisa Harding, MD Kristina M. Deligiannidis, MD Roger S. McIntyre, MD, FRCP

GH Research is exploring the therapeutic potential of Mebufotenin (GH001) across multiple depressive disorders, highlighted in a panel at the ACNP 2026 conference. Findings from a Phase 2b clinical trial reveal that GH001 provides rapid and significant antidepressant effects, particularly in treatment-resistant depression. The therapy has shown a good safety profile and beneficial effects on maternal functioning in postpartum depression. Overall, the results suggest that GH001 could fulfill a crucial need in the psychiatric treatment landscape.

Read more →
GHRS
Jan 13, 2026
GHRSPhases

GH001 Improves Illness Severity, Anxiety Symptoms, and Quality of Life in Patients with Treatment-Resistant Depression Michael E. Thase, MD Department of Psychiatry, University of Pennsylvania and Corporal Michael J. Cre

GH001, a synthetic form of mebufotenin, demonstrates promising efficacy in improving illness severity, anxiety symptoms, and overall quality of life in patients suffering from treatment-resistant depression (TRD). This drug has been well tolerated in early-stage trials, addressing an unmet need for effective treatment options in this patient population. The Phase 2b trial revealed significant improvements in depressive symptoms over a six-month period, suggesting GH001 may offer rapid therapeutic benefits for those with limited treatment responses.

Read more →
GHRS
Jan 8, 2026
GHRSPhases
▼ -13.4%on this newsshared move

Figure 3. Double-Blind Part: MADRS Suicidality Item 10 Responses at Baseline and Day 8 GH001 (n=40) Placebo (n=41) 6 5 4 3 2 1 0 100 90 80 70 60 50 40 30 20 10 0 Baseline Day 8 Baseline Day 8 Percentage of Patients by MA

The Phase 2b trial of GH001, a treatment for treatment-resistant depression (TRD), shows promising results. In a controlled environment, patients exhibited significant reductions in depressive symptoms over a six-month open-label extension phase. The treatment was well tolerated, and there were no incidents of treatment-emergent suicidal intent, emphasizing safety. However, one patient did report temporary suicidal ideation, which resolved spontaneously, highlighting the need for careful patient selection.

Read more →
GHRS
Jan 5, 2026
GHRSFDA Updates
▲ +16.8%on this newsshared move

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH Research PLC announced that the FDA has lifted the clinical hold on its IND for GH001, allowing U.S. subject enrollment. This development is a significant milestone for the company, as it prepares to initiate a global pivotal Phase 3 program in 2026. Experts have noted GH001's potential to transform treatment for patients with treatment-resistant depression.

Read more →
GHRS
Jan 5, 2026
GHRSFDA Updates
▲ +16.8%on this newsshared move

GH Research to Announce IND Status for GH001

GH Research PLC will announce the status of its Investigational New Drug Application for GH001 on January 5, 2026. The company is focused on developing treatments for treatment-resistant depression (TRD) and has reported positive results from its Phase 2b trial. The update will provide insights into their pivotal Phase 3 program.

Read more →
GHRS
Nov 24, 2025
GHRSPhases

GH001 Improves Illness Severity, Anxiety Symptoms, and Quality of Life in Patients with Treatment-Resistant Depression Michael E. Thase 1,2 *, Bernhard T. Baune 3,4,5 , Narc s Cardoner 6 , Kelly Doolin 7 , Rosa Maria Due

The Phase 2b trial for GH001 demonstrated its efficacy in treating patients with treatment-resistant depression (TRD), revealing significant improvements in depressive symptoms, anxiety, and overall quality of life. In the study involving 81 patients, GH001 led to a notable reduction in scores on various assessment scales such as MADRS, CGI-S, and HAM-A. Remarkably, 73% of the patients who completed the open-label extension achieved remission. The findings suggest sustained benefits over a six-month period with few required treatments, showcasing GH001's potential as an effective therapy for TRD.

Read more →
GHRS
Nov 6, 2025
GHRSFDA Updates

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

GH Research PLC reported its Q3 2025 financial results, highlighting progress in its clinical development of GH001 for treatment-resistant depression. The company received FDA communication regarding a clinical hold, with one topic remaining to be addressed. The Phase 2b trial results showed significant efficacy, and the company plans to initiate a global pivotal program in 2026.

Read more →
GHRS
Nov 6, 2025
GHRSGeneral

GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended September 30, Nine months ended

GH Research PLC reported its unaudited interim financial results for the three and nine months ending September 30, 2025. The company experienced a comprehensive loss of $14.1 million during the recent quarter, reflecting increased operating expenses. Notably, the company raised $139.8 million from a public offering, contributing to a rise in total assets to $302 million and a strong cash position of $249.7 million. Despite the financial challenges, the company remains focused on developing new therapies for treatment-resistant depression.

Read more →
GHRS
Oct 17, 2025
GHRSPhases

Suicidal Ideation and Behavior in Patients With Treatment-Resistant Depression Treated With GH001 Sanjay J. Mathew 1,* , Bernhard T. Baune 2,3,4 , Narc s Cardoner 5 , Wies aw J. Cuba a 6 , Kelly Doolin 7 , Rosa Maria Due

A Phase 2b trial of GH001, a synthetic form of mebufotenin, has demonstrated its potential as a treatment for patients with treatment-resistant depression (TRD). The trial involved 81 patients and showed that GH001 resulted in significant improvements in depressive symptoms without increasing the risk of suicidal ideation or behavior. While one moderate treatment-emergent adverse event of suicidal ideation was noted, it resolved spontaneously, and overall, the therapy was well tolerated. These results suggest that GH001 may be a promising option for addressing the unmet needs in TRD management.

Read more →

About GH Research PLC

73 employees ghres.com
BIOPHARMAWATCH ELITE PLUS
Trade the next GHRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime